California-Based Shennon Biotechnologies Raises $12M in Funding

The round also saw backers Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, Saras Capital, DCVC, Foundation Capital, and AV8 Ventures.

The company will use the funding to advance its technology platform and oncology pipeline.

About Shennon Biotechnologies

Founded in 2021, by Li Sun, Shennon Biotechnologies is developing precision immunotherapies for solid tumors through an integrated technology platform covering target discovery functional screening, computational therapeutic design and safety prediction.

Read More:

Core offerings include:

• Antibody-based T-cell engagers
• TCR-based T-cell engagers
• Target discovery
• Ultra-high-throughput functional screening
• Computational binder prediction and optimization

Leadership Comments

“ShennonBio was founded to address fundamental challenges that have limited the development of precision immunotherapies, from identifying differentiated targets and highly functional therapeutic binders to predicting potential safety risks before candidates reach the clinic,” said Li Sun, Ph.D., Founder, President and Chief Technology Officer, ShennonBio.

“ShennonBio has spent the last several years building a differentiated foundation spanning proprietary human data, target discovery, functional screening, therapeutic design and safety prediction,” said Dr. Konto. “What attracted me to the Company is the opportunity to translate those capabilities into a new generation of precision immunotherapies.

Read More: